Cerebral Cortex, Vol. 13, No. 7, 736-748,
July 2003
© 2003 Oxford University Press
Neurogenesis in Cerebral Heterotopia Induced in Rats by Prenatal Methylazoxymethanol Treatment
Molecular Neuroanatomy Laboratory, Experimental Neurophysiology Department, Neurological Institute C. Besta, via Celoria 11 and , 1 Department of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133 Milano, Italy
We have previously demonstrated that the antiproliferative agent methylazoxymethanol acetate (MAM) is able to induce in rats cerebral heterotopia that share striking similarities with those observed in human periventricular nodular heterotopia (PNH), a cerebral dysgenesis frequently observed in human patients affected by drug-resistant focal epilepsy. In this study, we investigated the time-course of neurogenesis in the cerebral heterotopia of MAM-treated rats, with the idea of understanding why PNH develop in human patients. For these goals, we analyzed the cytoarchitectural features, the time of neurogenesis and the cellular phenotype of the heterotopia, by means of BrdU immunocytochemistry and confocal immunofluorescence experiments. Our data demonstrate that the different types of heterotopia in MAM-treated rats are formed through the same altered neurogenetic process, which follows quite organized neurogenetic gradients. The MAM-induced ablation of an early wave of cortical neurons is sufficient to alter per se the migration and differentiation of subsequently generated neurons, which in turn set the base for the formation of the different heterotopic structures. The neurogenesis of MAM-induced heterotopia may explain the origin and intrinsic epileptogenicity of periventricular nodular heterotopia in human patients.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
B. Bolon, R. Garman, K. Jensen, G. Krinke, B. Stuart, and An Ad Hoc Working Group of the STP Scientific and A 'Best Practices' Approach to Neuropathologic Assessment in Developmental Neurotoxicity Testing--for Today Toxicol Pathol, April 1, 2006; 34(3): 296 - 313. [Abstract] [Full Text] [PDF] |
||||
